Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
BRCA1/2&DNA Repair Gene Testing
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Combination Immunotherapy Prolongs Overall Survival of mCRC 2019-08-05
The results of a phase II study showed that the clinical efficacy of the combination of durvalumab and tremelimumab in patients with mCRC. Furthermore, the results indicated that bTMB can be used to select patients who benefit from immunotherapy treatment
Talazoparib Shows Clinical Benefit In PALB2-Mutated HER2-Negative Metastatic Breast Cancer Patients 2019-08-05
Talazoparib may offer the therapeutic opportunity for HER2-negative breast cancer patients who have a non-BRCA HRR mutation, especially for those with a PALB2 mutation.
Ivosidenib shows clinical activity in advanced cholangiocarcinoma patients with IDH1 mutation 2019-08-05
IDH1 is mutated in up to 25% of cholangiocarcinoma patients, and according to a phase 1 trial, ivosidenib demonstrated clinical benefit among previously treated IDH1-mutated cholangiocarcinoma patients.
STK11 and/or KEAP1 genomic alterations showed lack of clinical benefits from addition of immunotherapy to chemotherapy in NSCLC patients 2019-07-04
A study analyzed the clinical impact of STK11 and/or KEAP1 genomic alterations in NSCLC patients received chemo-immunotherapy. The results demonstrated that the addition of immunotherapy to chemotherapy did not provide clinical benefit in patients with ST
Olaparib maintenance therapy significantly prolongs the progression-free survival of BRCA-mutated metastatic pancreatic cancer 2019-07-04
Olaparib as maintenance therapy showed clinical benefit in prolonging progression-free survival (PFS) of pancreatic cancer who had a germline BRCA mutation in a phase III POLO study.
A novel KRAS inhibitor shows promising anti-tumor activity 2019-07-04
From a phase 1 study presented at the 2019 ASCO Annual Meeting, the KRAS G12C inhibitor AMG 510 showed encouraging anti-tumor activity in patients with KRAS G12C mutation
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
